Gregory J. Flesher
Net Worth
Last updated:
What is Gregory J. Flesher net worth?
The estimated net worth of Mr. Gregory J. Flesher is at least $13,351,677 as of 21 May 2019. He owns shares worth $407,987 as insider, has earned $28,570 from insider trading and has received compensation worth at least $12,915,120 in Eledon Pharmaceuticals, Inc. and Reneo Pharmaceuticals, Inc..
What is the salary of Gregory J. Flesher?
Mr. Gregory J. Flesher salary is $1,800,000 per year as Consultant in Eledon Pharmaceuticals, Inc.. He also receives $528,780 as Pres, Chief Executive Officer & Director in Reneo Pharmaceuticals, Inc..
How old is Gregory J. Flesher?
Mr. Gregory J. Flesher is 55 years old, born in 1970.
What stocks does Gregory J. Flesher currently own?
As insider, Mr. Gregory J. Flesher owns shares in 2 companies:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | Consultant | 156,918 | $2.6 | $407,987 |
| Reneo Pharmaceuticals, Inc. (RPHM) | Pres, Chief Executive Officer & Director | 8,000 | $0 | $0 |
What does Eledon Pharmaceuticals, Inc. do?
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
What does Reneo Pharmaceuticals, Inc. do?
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Gregory J. Flesher insider trading
Eledon Pharmaceuticals, Inc.
Mr. Gregory J. Flesher has made 2 insider trades in 2019, according to the Form 4 filled with the SEC. Most recently he sold 2,937 units of ELDN stock worth $5,613 on 21 May 2019.
The largest trade he's ever made was exercising 11,701 units of ELDN stock on 20 May 2019. As of 21 May 2019 he still owns at least 156,918 units of ELDN stock.
Eledon Pharmaceuticals key executives
Eledon Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. David-Alexander C. Gros (53) Chief Executive Officer & Non Independent Director
- Dr. Steven N. Perrin Ph.D. (59) Pres, Chief Scientific Officer & Non Independent Director
- Mr. Gregory J. Flesher (55) Consultant